Inhibition of epithelial‐to‐mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma
The FEBS Journal · 2023
DOI: 10.1111/febs.16879 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2023. Verfasst von Kai-Zhou Jin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Fudan University Shanghai Cancer Centre, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Intrinsic drug resistance mechanisms of tumor cells often reduce intracellular drug concentration to suboptimal levels. Epithelial‐to‐mesenchymal transition (EMT) is a pivotal process in tumor progression and metastasis that confers an aggressive phenotype as well as resistance to chemotherapeutics. Therefore, it is imperative to develop novel strategies and identify new targets to improve the overall efficacy of cancer treatment. We developed SN38 (active metabolite of irinotecan)‐assembled glycol chitosan nanoparticles (cSN38) for the treatment of pancreatic ductal adenocarcinoma (PDAC). Furthermore, cSN38 and the TGF‐β1 inhibitor LY364947 formed composite nanoparticles upon self‐assembly (cSN38 + LY), which obviated the poor aqueous solubility of LY364947 and enhanced drug sensitivity. The therapeutic efficacy of cSN38 + LY nanotherapeutics was studied in vitro and in vivo using suitable models. The cSN38 nanoparticles exhibited an antitumor effect that was significantly attenuated by TGF‐β‐induced EMT. The cellular uptake of SN38 was impeded during EMT, which affected the therapeutic efficacy. The combination of LY364947 and cSN38 markedly enhanced the cellular uptake of SN38, increased cytotoxic effects, and inhibited EMT in PDAC cells in vitro . Furthermore, cSN38 + LY significantly inhibited PDAC xenograft growth in vivo . The cSN38 + LY nanoparticles increased the therapeutic efficacy of cSN38 via repressing the EMT of PDAC cells. Our findings provide a rationale for designing nanoscale therapeutics to combat PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Centre, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Shanghai Pancreatic Cancer Institute, China.
- Pancreatic Cancer Institute, Fudan University, Shanghai, China.
- Institute of Clinical Medicine Research, Zhejiang Provincial People's Hospital, Hangzhou Medical College, China.
- Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
ORCID-Profile: Wei Chen, Long-Yun Ye, Wei-Ding Wu
Förderung
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Jin, K. Z., Wu, Y., Zheng, X. X., Li, T. J., Liao, Z. Y., Fei, Q. L., Zhang, H. R., Shi, S. M., Sha, X., Yu, X. J., Chen, W., Ye, L. Y., & Wu, W. D. (2023). Inhibition of epithelial‐to‐mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. The FEBS Journal. https://doi.org/10.1111/febs.16879
Vancouver
Jin KZ, Wu Y, Zheng XX, Li TJ, Liao ZY, Fei QL, et al. Inhibition of epithelial‐to‐mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. The FEBS Journal. 2023. doi:10.1111/febs.16879
BibTeX
@article{Jin2023,
author = {Jin, Kai-Zhou and Wu, Ying and Zheng, Xiao-Xiao and Li, Tian-Jiao and Liao, Zhen-Yu and Fei, Qing-Lin and Zhang, Hui-Ru and Shi, Sai-Meng and Sha, Xin and Yu, Xian-Jun and Chen, Wei and Ye, Long-Yun and Wu, Wei-Ding},
title = {Inhibition of epithelial‐to‐mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma},
journal = {The FEBS Journal},
year = {2023},
doi = {10.1111/febs.16879}
}
EUVIMED